Table 3.

HIV-1-specific ELISA antibody responses stratified by high vs low neutralization against MVA or VACV

Day Post Vaccination a	Study Arm b	Neutralization Assay c	ELISA antigen d	High Neutralization e	Low Neutralization	p value f
98	rMVA-HIV(5)	VACV	p24	6/16 (37.5%)	0/14 (0%)	0.019
		MVA	p24	3/15 (20.0%)	3/15 (20.0%)	1.000
		VACV	gp120	14/16 (87.5%)	6/14 (42.9%)	0.019
		MVA	gp120	10/15 (66.7%)	10/15 (66.7%)	1.000
154	rMVA-HIV(5)	VACV	gp120	13/15 (86.7%)	7/14 (50.0%)	0.050
		MVA	gp120	12/15 (80.0%)	8/14 (57.1%)	0.245
210	rMVA-HIV(2)/rFPV-HIV(3)	VACV	p24	7/8 (87.5%)	10/17 (58.8%)	0.205
		MVA	p24	9/10 (90.0%)	9/16 (56.3%)	0.099
	rMVA-HIV(5)	VACV	gp120	13/14 (92.9%)	5/14 (35.7%)	0.004
		MVA	gp120	10/14 (71.4%)	8/14 (57.1%)	0.695

^aEnrollment is concurrent with the first vaccination; only time points with at least one comparison with p < 0.100 are shown

^brMVA-HIV(5): 10⁹ pfu/2 mL of rMVA for 5 vaccinations; rMVA-HIV(2)/rFPV-HIV(3): 10⁹ pfu/2 mL of rMVA for 2 vaccinations followed by 10⁹ pfu/2 mL of rFPV for 3 vaccinations

^cNeutralizing antibodies (NAb) assayed against either VACV-luciferase or MVA-luciferase

^dBinding antibodies measured against Gag (p24) or Env (gp120)

^eHigh neutralization: responder and ≥ median Nab titres for responders from the group; low neutralization: non-responders or < median titres for responders from the group

^fp value determined by two-tailed Fisher’s exact test comparing high neutralization vs low neutralization